Conflicts of interest

The authors have made the following disclosures: Quentin Anstee reports grants from Abbvie; personal fees and other from Genfit and Allergan/Tobira; other from Intercept, Pfizer, Janssen, Eli Lilly, E3Bio, Novartis, Raptor, Gilead, Grunthal, and Inventiva, outside the submitted work.

David DeBrota reports personal fees from Eli Lilly, outside the submitted work.

Claudia Filozof reports personal fees from Covance, outside the submitted work.

Joanne Imperial reports personal fees from FibroGen and Conatus, outside the submitted work.

Veronica Miller reports grants from the American Association for the Study of Liver Diseases, Abbvie, Allergan, AstraZeneca R&D, Biogen, Bird Rock Bio, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, ConSynance Therapeutics, Inc., Covance, DeuteRx, LLC, DiaPharma Group, Inc., DS Biopharma, European Association for the Study of the Liver, Echosens North America Inc., Eli Lilly and Company, Enanta Pharmaceuticals, Inc., Exalenz Bioscience Ltd., FibroGen, Inc., Fractyl Laboratories Inc., Galectin Therapeutics, Inc., Genfit SA, Gilead Sciences, Inc., GlaxoSmithKline, ICON PLC, Immuron Limited, Intercept Pharmaceuticals, Inventiva Pharma, Ironwood Pharmaceuticals, Madrigal Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, MediciNova, Inc., Merck & Co., Inc., NGM Biopharmaceuticals, Nimbus Therapeutics, Nitto BioPharma, Inc., Novartis Pharma AG, Novo Nordisk, NuSirt Biopharma, OWL Metabolomics, Pfizer, Inc., Raptor Pharmaceuticals, Resonance Health Ltd., Roivant Sciences, Inc., Shire International GmbH, John Joseph Sninsky, Susan Bardsley Sninsky, SomaLogic, Inc., Takeda Pharmaceuticals International, Inc., Target PharmaSolutions, Teva Pharmaceutical Industries, VLVbio, Zafgen, Inc., and Zealand Pharma, outside the submitted work. Andrew Muir reports grants and personal fees from Abbvie, grants and personal fees from BMS, Gilead, Janssen, Merck, Shire; and grants from NGM Pharmaceuticals, and Roche, outside the submitted work. Arun Sanyal reports personal fees from Sanyal Bio, Pfizer, Nimbus, Nitto Denko, HemoShear Therapeutics, Lilly, UptoDate, Elsevier, Quintiles, and Salix; grants from Conatus, Salix, Gilead, Novartis, Galectin, Bristol Myers, Merck, Astra Zeneca, Boehringer Knoll, Tobira, Intercept, Novo Nordisk, Malinkrodt, Octeta, and Cumberland; other from Akarna, GenFit, Syntlogic, Ardelyx, Covance, outside the submitted work. Brent Neuschwander-Tetri reports personal fees from Allergan, Boehringer Ingelheim, Bristol-Myers Squibb, Conatus, Consynance, Enanta, Galmed, Janssen, MedImmune, Nimbus, Novartis, Pfizer, Receptos, Tobira, and Zafgen, outside the submitted work.

The remaining authors disclose no conflicts.